4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly earnings of $0.86 per share which beat the analyst consensus estimate of $(0.83) by 203.61 percent. This is a 230.3 percent increase over losses of $(0.66) per share from the same period last year. The company reported quarterly sales of $14.00 thousand which missed the analyst consensus estimate of $382.57 thousand by 96.34 percent. This is a 50.00 percent decrease over sales of $28.00 thousand the same period last year.